Based on these findings, targeting glutaminolysis and OXPHOS is suggested as an effective therapeutic approach for ESCC with a dysregulated Fbxo4-cyclin D1 axis and for overcoming palbociclib resistance. Here, CCND1 is linked to esophageal squamous cell carcinoma.